Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#4390 FDG uptake in lung neuroendocrine tumours and its association with tumour characteristics and prognosis

Introduction: The utility of fluorodeoxyglucose positron emission tomography (FDG-PET) in the evaluation of lung neuroendocrine tumours (L-NETs) remains debated.

Conference:

Presenting Author:

Authors: Twito O, Muzykovskaia E, Frenkel M,

Keywords: lung neuroendocrine tumour, imaging, FDG-PET,

#4339 Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN)

Introduction: Accurate contouring for [68Ga]DOTATATE PET in NEN is challenging due to differing physiological uptake for the liver, spleen and other organs. This poses a significant problem for absolute thresholding algorithms using a single threshold, even if the threshold is based on liver uptake (as suggested for FDG PET by PERCIST). Improved contouring of PET to measure [68Ga]DOTATATE-avid tumour volume could help clinical translation of this potential biomarker.

Conference:

Presenting Author: Chan D

Authors: Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z,

Keywords: prognostic biomarker, PET imaging, [68Ga]DOTATATE, Total Lesion Volume,

#4097 Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multicentre study

Introduction: 18F-FDG PET/CT avidity predicts for higher histological grade and worse prognosis in patients with NEN. However, there is less evidence regarding the role of FDG-avid tumor volume in predicting prognosis.

Conference:

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Conner A, Mileva M,

Keywords: prognostic biomarker, PET imaging, 18F-FDG, metabolic tumor volume,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,